NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis today reported that its total revenues for the first half of 2018 jumped 83 percent year over year, driven by a rise in cartridge consumption and collaboration revenue.
For the six months ended June 30, Biocartis' total revenues soared to €12.7 million ($14.8 million) from €7.0 million in 2017.